Skip to main content
Veterinary Medicines

Rycarfa 50 mg tablets for dogs

Authorised
  • Carprofen

Product identification

Medicine name:
Rycarfa 50 mg tablets for dogs
Rycarfa 50 mg Tablet
Rycarfa 50 mg Comprimé
Rycarfa 50 mg Tablette
Active substance:
  • Carprofen
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Carprofen
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AE91
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Blister (OPA/Al/PVC-Al): 20 tablets (10 tablets/blister) in a box
  • Blister (OPA/Al/PVC-Al): 50 tablets (10 tablets/blister) in a box
  • Blister (OPA/Al/PVC-Al): 100 tablets (10 tablets/blister) in a box
  • Blister (OPA/Al/PVC-Al): 500 tablets (10 tablets/blister) in a box

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • Krka d.d. Novo Mesto
  • Tad Pharma GmbH
  • Krka-Farma d.o.o.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V456782
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0316/002
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
Dutch (PDF)
Published on: 22/03/2022
French (PDF)
Published on: 22/03/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
French (PDF)
Published on: 22/03/2022
German (PDF)
Published on: 22/03/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."